Primus In News
Indian pharma eyes US gains as $63.7 bn patent cliff nears: Analysts
29-06-2025
Nilaya Varma, Group CEO and Co-founder, Primus Partners, shared his view on the changing landscape of the global generics industry. He highlighted that India's pharmaceutical exports have grown significantly—from $15 billion in 2013–14 to nearly $28 billion over the last decade—driven by the country’s 750+ USFDA-approved facilities and expanding expertise in complex generics and biosimilars. With major global players scaling down operations, Indian companies are well-placed to seize the $180 billion loss-of-exclusivity opportunity
Explore Related Insights
- Homing in: The startuppers who want to transform their own backyards
- Aviation leasing watchdog puts India on watchlist after NCLT’s GoFirst order, assigns ‘negative’ outlook
- PM Modi turns 75: Sensex rallied up to 245% under his leadership; what lies ahead?
- Gold, silver hit fresh lifetime highs: Should you invest in precious metals this Dhanteras?
